Sugi Predict

Sugi Predict / Compounds / SCHEMBL2477620

SCHEMBL2477620

SCHEMBL2477620

Cc1ccc([CH]c2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 2/20 0.53
▸ LMNA P02545 1/20 0.53
▸ TSHR P16473 1/20 0.53
▸ ALOX12 P18054 1/20 0.53
▸ CYP2A6 P11509 1/20 0.48
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ HPGD P15428 3/20 0.45
▸ MAPT P10636 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ CYP1B1 Q16678 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.44
▸ NFE2L2 Q16236 3/20 0.43
▸ POLB P06746 2/20 0.41
▸ PPARG P37231 1/20 0.41
▸ TRPM8 Q7Z2W7 1/20 0.41
▸ EGFR P00533 1/20 0.41
▸ MMP1 P03956 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1149391 0.88 CYP2A6 (0.58) ACHECYP2A6NPC1RAB9ASMN1; SMN2
SCHEMBL2357484 0.85 ALDH1A1 (0.50) LMNATSHRCYP2A6SMN1; SMN2MAPT
SCHEMBL1239547 0.83 NFE2L2 (0.61) ACHELMNATSHRALOX12HPGD
SCHEMBL700269 0.83 NFE2L2 (0.61) ACHELMNATSHRALOX12HPGD
SCHEMBL4585859 0.83 NFE2L2 (0.61) ACHELMNATSHRALOX12HPGD
SCHEMBL7164327 0.83 NFE2L2 (0.61) ACHELMNATSHRALOX12HPGD
SCHEMBL4585865 0.83 NFE2L2 (0.61) ACHELMNATSHRALOX12HPGD
SCHEMBL4585867 0.83 NFE2L2 (0.61) ACHELMNATSHRALOX12HPGD
SCHEMBL840358 0.83 NFE2L2 (0.61) ACHELMNATSHRALOX12HPGD
SCHEMBL1302 0.82 ALDH1A1 (0.53) LMNATSHRCYP2A6SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2800756-B1 PEPTIDE C ALPHA-AMIDES, METHODS FOR PREPARING SAME AND USES THEREOF AS PRECURSORS OF PEPTIDE C ALPHA-THIOESTERS FOR PROTEIN SYNTHESIS CENTRE NAT RECH SCIENT (FR) 2018-04-25 — — EP claimed
US-9683015-B2 Peptide C alpha-amides, methods for preparing same and uses thereof as precursors of peptide C alpha-thioesters for protein synthesis CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) 2017-06-20 — — US claimed
EP-2906970-B1 HIGH REFRACTIVE INDEX OPHTHALMIC DEVICE MATERIALS WITH REDUCED TACK NOVARTIS AG (CH) 2016-11-23 — — EP claimed
EP-2800756-A1 PEPTIDE C ALPHA-AMIDES, METHODS FOR PREPARING SAME AND USES THEREOF AS PRECURSORS OF PEPTIDE C ALPHA-THIOESTERS FOR PROTEIN SYNTHESIS Centre National de la Recherche Scientifique (CNRS) (FR) 2014-11-12 — — EP claimed
US-8492384-B2 Imidazolylalkylcarbonyl derivatives as calcium channel modulators and preparation method thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2013-07-23 — — US claimed
WO-2013102723-A1 PEPTIDE C ALPHA-AMIDES, METHODS FOR PREPARING SAME AND USES THEREOF AS PRECURSORS OF PEPTIDE C ALPHA-THIOESTERS FOR PROTEIN SYNTHESIS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) 2013-07-11 — — WO claimed
EP-2231613-B1 MONTELUKAST BENZHYDRYL PIPERAZINE SALTS AND PROCESS FOR PREPARATION THEREOF TORRENT PHARMACEUTICALS LTD (IN) 2011-10-12 — — EP claimed
US-20090325979-A1 NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2009-12-31 — — US claimed
EP-1150565-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION bioscience AG (DE) 2001-11-07 — — EP claimed
WO-2000045635-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2000-08-10 — — WO claimed
EP-4370528-A1 AQUEOUS SOLID PHASE PEPTIDE SYNTHESIS Polypeptide Laboratories Holding (PPL) AB (SE) 2024-05-22 — — EP disclosed
CN-117897392-A Aqueous solid phase peptide synthesis 多肽实验室(PPL)控股公司 2024-04-16 — — CN disclosed
CN-114805487-B Polypeptide compound and application thereof 成都诺和晟泰生物科技有限公司 2024-03-12 — — CN disclosed
CN-112912390-B GLP-1 analogues and methods of preparation 北京费森尤斯卡比医药有限公司 2023-12-15 — — CN disclosed
CN-113045625-B Polypeptides as somatostatin receptor agonists and uses thereof 成都诺和晟泰生物科技有限公司 2023-11-07 — — CN disclosed
US-5011989-A Asymmetric reducing agents SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1991-04-30 — — US disclosed
US-4892887-A ANTITUMOR YALE UNIVERSITY (US) 1990-01-09 — — US disclosed
EP-0293130-A2 Dimers of parathyroid hormone antagonists MERCK & CO. INC. (US) 1988-11-30 — — EP disclosed
US-4684747-A ANTITUMOR, ALKYLATING AGENTS YALE UNIVERSITY (US) 1987-08-04 — — US disclosed
US-4251655-A GASTRIC ACID ANTISECRETORY AGENTS MCNEILAB, INC. (US) 1981-02-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325979-A1 NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF CACNA1B, CACNA1C, ORAI1 ACHE 356/4885LMNA 936/4885TSHR 3065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.